Ambah-PSI Unveils the First Ibuprofen Intravenous (IV) Infusion in the World at CPhI in Barcelona

Ambah-PSI, the leading sterile injectable manufacturer in the Middle East and Africa (MEA) region is pleased to announce its newest product “Ambaprofen”—the first Ibuprofen intravenous (IV) infusion in the world (400mg/100ml), besides showcasing its comprehensive portfolio of injectable solutions at CPhI Worldwide (Stand 7D84 and 7D81), one of the pharmaceutical industry’s highest profile events, being held this week in Barcelona, Spain.

Successfully registered as Ambaprofen ® and Ambafen ® (Ibuprofen 400mg/100ml IV Infusion) through respective health authorities in Germany, Spain, and Saudi Arabia, its patent has been granted by the European Patent Office (EPO patent no: 2636406); United States Patent and Trademark Office (uspto Patent No: US 9,351,926 B2); King Abdulaziz City for Science and Technology (KACST patent no: 4219) and GCC Patent Office (GCC patent no: GC0003918) for its dosage form with the approval of the European Medicines Agency (EMA).

Ambaprofen (Ibuprofen 400mg/100ml IV Infusion), with its analgesic, antipyretic and anti-inflammatory properties is a safe option to treat pain and fever in hospitalized patients.

CPhI Barcelona 2016 is the world's leading European pharmaceutical exhibition, bringing together more than 36,000 pharma industry professionals over three days.

2,500+ exhibitors from 150+ countries gather at the event to network and take advantage of more than 100 free industry seminars. Every sector of the pharmaceutical market is represented under one roof.

Indeed, attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and customers, launch new products, promote brands, and stay updated on the latest industry trends and market news. This year, CPhI is taking place in Barcelona and running from October 4th and 6th.

For further details contact: ambaprofen@psi.com.sa